Skip to search formSkip to main contentSkip to account menu

recurrent small cell lung cancer

Known as: Relapsed Small Cell Lung Carcinoma, recurrent SCLC, lung cancer, recurrent small cell 
The reemergence of small cell carcinoma of the lung after a period of remission.
National Institutes of Health

Related topics

Related topics

23 relations
BronchiChestEndocrine systemEpithelial Cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Nearly all patients with small cell lung cancer (SCLC) eventually relapse with chemoresistant disease. The molecular mechanisms… 
Highly Cited
2012
Highly Cited
2012
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
Purpose: This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung… 
Highly Cited
2011
Highly Cited
2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Highly Cited
2009
Highly Cited
2009
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
The topoisomerase-I (topo-I) inhibitor topotecan, derivative of camptothecin, is the only registered drug for relapsed small cell… 
2008
2008
Management of recurrent small cell lung cancer.
Small cell lung cancer remains one of the more frustrating malignancies for oncologists to treat. Although responses to initial… 
Review
2004
Review
2004
Emerging role of weekly topotecan in recurrent small cell lung cancer.
Small cell lung cancer (SCLC) is an aggressive tumor that often metastasizes before the primary cancer is diagnosed. Patients… 
Review
2004
Review
2004
Topotecan in the treatment of recurrent small cell lung cancer: an update.
Small cell lung cancer (SCLC) is an aggressive malignancy with a high propensity for early regional and distant metastasis… 
Review
2004
Review
2004
Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status.
Topotecan is the only single-agent therapy approved by the U.S. Food and Drug Administration for the treatment of patients with… 
Highly Cited
1997
Highly Cited
1997
126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study
Highly Cited
1993
Highly Cited
1993
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)